FORMULATION AND EVALUATION OF EXTENDED RELEASE MICROCAPSULES OF LAMIVUDINE - OBJECTIVES

-

 

OBJECTIVES

 

            The main objective of any drug therapy is to achieve a desire concentration of drug in blood or tissue, which is therapeutically effective and non toxic for an extended period of time. This can be achieved by proper design of sustained release dosage regimen. The microencapsulation is one among these which can be utilized successesfully to design the oral sustained release dosage form1, 2.

 

            Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus(HIV) infection. Lamuvudine (Epivir-HBV) is ued to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs)3.

 

            .Lamivudine is a pyrimidene analogue reverse tanscriptase enzyme inhibitors active against HIV virus. It is metabolized to actice triphosphate from by multiple kinase. The triphosphate form completes with deoxycytidine triphosphate for binding reverse transcriptase and incorporation of 3-tc from viral DNA results in chain termination. Lamivudine is rapidly absorbed orally with 85% bioavailability and distributed widely in the body. Lamivudine is primarily 70% of the drug excreted unchanged in urine with elimination half life of 5-7 hrs3,4.

 

            As per the through literature survey it is confirmed that very little work on Lamivudine microcapsule is reported. There are no reports found on microencapsulation of Lamivudine. Hence, the present study is aiming to design the microencapsulation dosage form of the Lamivudine, by utilizing naturally occurring olibanum gum resin after its suitable extraction.

The present work was an attempt:

1.      To develop Sustained release matrix tablets contains Lamivudine by using special excipient like  HPMC, EC and Magnesium stearate.

2.      To evaluate for the pre-compression characteristics of powder mixture like bulk density, flow property, angle of repose, compressibility index etc.

3.      To evaluate the post-compression characteristics of the tablet like hardness, friability, disintegration time, dispersion time, wetting time and water absorption ratio etc.

4.      To carry out in vitro dissolution studies of the tablet formulations.

5.      To carry out stability studies according to ICH guidelines.

 

PLAN OF WORK

METHOD OF COLLECTION OF DATA:

1.      The selected drug was characterized and evaluated for its physicochemical properties like solubility and compatibility with excipients.

2.      To identify the suitable excipients alone or in combine for further processing.

3.      To carry out pre-formulation studies like organoleptic properties, Bulk density, tapped density, Angle of repose, Compressibility index of the powder mixture (drug and excipients).

4.      To formulate various formulations of the drug containing different ratio of the polymer or in combination.

5.      To evaluate the compressed tablet for hardness, friability, disintegration time, In-vitro dispersion time, wetting time and In-vitro dissolution time, etc.

6.      The optimized formulation will be subjected to stability studies according to ICH guidelines.

7.      The data so obtained will be subjected for statistical analysis.

8.      The selected drug shall be characterized and evaluated for its physicochemical properties like solubility and compatibility with excipients.

9.      To identify the suitable excipients alone or in combine for further processing.

10.  To carry out pre-formulation studies like organoleptic properties, Bulk density, tapped density, Angle of repose, Compressibility index of the powder mixture (drug and excipients).

11.  To formulate various formulations of the drug containing different ratio of the hydrophilic polymer or in combination.

12.  To evaluate the compressed tablet for hardness, friability, disintegration time, In-vitro dispersion time, wetting time and In-vitro dissolution time, etc.

13.  The optimized formulation will be subjected to stability studies according to ICH guidelines.

14.  The data so obtained will be subjected for statistical analysis.

The preliminary data required for the experimental study was obtained from

1.      CD-Rom search available at National Center for Scientific Information (NCSI), Indian institute of Sciences (IISc), Bangalore.

2.      Journals,

3.      Analytical chemistry Books ,

4.      Library,

5.      Relevant Books,

6.      Internet Sources ,

7.      Scientific abstracts.

Comments

Post a Comment

Popular posts from this blog

Chemical test for Tragacanth

-
Chemical test for Tragacanth Organoleptic test: Appearance: Crystalline                                                          tragacanth Colour: White or faint yellow                                                 tragacanth Odour: None                                                                           tragacanth Taste: Mucilaginous                                                                tragacanth Solubility: Insoluble in alcohol, partially soluble in water      tragacanth Chemical test: SI.No. Test Observation Inference 1. To 4ml of 0.5%w/v solution add  0.5ml of HCl and heat for 30minutes on water bath Divide the hydrolyzed product in 2 parts a)       1 st part=Add 1.5ml of NaOH solution to neutralize and add Fehling’s solution A and B in equal quantities(mixed before) and warm over water bath. b)       2 nd part= Add barium chloride solution Red ppt o
Read more

MINOR DISORDERS OF NEW BORN AND ITS MANAGEMENT - NURSING ASSIGNMENT

-
INTRODUCTION         Neonatal health problems are frequently found ranging from minor physical or physiological peculiarities to the serious life threatening illnesses. Minor problems should not be ignored lightly without adequate assessment of the conditions. Early diagnosis and management of the serious problems help to overcome life long disability and to reduce neonatal morbidity and mortality. Nurses are responsible to manage the minor problems and to detect the serious problems for early and prompt management along with appropriate nursing interventions and support to the mother. MINOR DISORDERS OF NEW BORN 1. VOMITING         Vomiting is one of the common manifestations in the neonates. Regurgitation after feeds should not be confused with vomiting. Mucus vomiting often hinged with blood is quite common soon after birth. It is due to irritation often gastric mucosa by the swallowed materials during birth. Causes: ·         Dietic ·         Over feeding
Read more

KANGAROO CARE - NURSING ASSIGNMENT

-
INTRODUCTION         Caring low birth weight baby is a great challenge for the neonatal care unit and the family. Number of low birth weighs baby is still for beyond the expected target in our country. The cost of the quality management of these babies is increasing day by day. Kangaroo care is low cost approach for the care of low birth weight baby. This method of care was introduced and popularized by Dr.Edger Ray, Dr.Martinez and Dr.Charpak in late 1970s. DEFINITION         Kangaroo Mother Care (KMC) is a special way of caring low birth weight infants by skin to skin contact if promotes their health and welling by effective thermal control, breast feeding and bonding. KMC is initiated in hospital and continued at home. COMPONENTS OF KMC         In KMC, the infant is continuously kept in skin contact by the mother and breastfed exclusively to the utmost extent.         The two components of KMC are; 1.    Skin to skin contact is provi
Read more